Food composition and pharmaceutical composition for inhibiting Sjogren's syndrome each containing Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP)
AssigneeBifido Co., Ltd.
InventorsGeun Eog Ji, Myeong Soo Park
Life of this patent
Estimating the term…
Abstract
Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.
Claims4
A method of inhibiting sialoadenitis symptom in a subject having Sjogren's syndrome comprising administering orally to said subject a food composition comprising an effective amount of an isolated strain of Bifidobacterium pseudocantenulatum C-RAPO deposited as KCTC13986BP.
A method of treating a subject having Sjogren's syndrome comprising administering orally to said subject a food composition comprising an effective amount of an isolated strain of Bifidobacterium pseudocantenulatum C-RAPO deposited as KCTC13986BP, wherein reduction of saliva secretion is inhibited in the subject.
A method of inhibiting sialoadenitis symptom in a subject having Sjogren's syndrome comprising administering orally to said subject a pharmaceutical composition comprising an effective amount of an isolated strain of Bifidobacterium pseudocantenulatum C-RAPO deposited as KCTC13986BP.
A method of treating a subject having Sjogren's syndrome comprising administering orally to said subject a pharmaceutical composition comprising an effective amount of an isolated strain of Bifidobacterium pseudocantenulatum C-RAPO deposited as KCTC13986BP, wherein reduction of saliva secretion is inhibited in the subject.
Dependencies are inferred from the claim text.